阿卡迪亚制药:将继续推进两项评估Remlifanserin治疗ADP的III期研究入组,并对III期项目实施方案进行修订
阿卡迪亚制药:将继续推进两项评估Remlifanserin治疗ADP的III期研究入组,并对III期项目实施方案进行修订
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.